Dyslipidemias associated with endocrine disorders: a position statement of the working group of the nutrition hormones and metabolism club of the italian society of endocrinology (SIE).
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Muscogiuri Giovanna, Albertelli Manuela, Arnaldi Giorgio, Barrea Luigi, Bellastella Giuseppe, Bonomi Marco, Caputo Marina, Caprio Massimiliano, Cignarelli Angelo, Di Gioia Ludovico, Frasca Francesco, Ferrari Davide, Gambineri Alessandra, Gasco Valentina, Gatto Federico, Giandalia Annalisa, Giordano Roberta, Infante Marco, Isidori Andrea, Malandrino Pasqualino, Occhi Gianluca, Pivonello Rosario, Prencipe Nunzia, Prodam Flavia, Simeoli Chiara, Verde Ludovica, Vignozzi Linda, Cannavò Salvatore, Giorgino Francesco, Colao Annamaria, Aimaretti Gianluca, Ferone Diego, Perrini Sebastio
Аннотация
METHODS: A comprehensive review of current literature was performed, integrating epidemiological, mechanistic, and clinical data on lipid alterations across major endocrine diseases. Expert consensus was used to interpret evidence and formulate recommendations for clinical practice.
RESULTS: Distinct and disease-specific dyslipidemic patterns were identified across conditions involving the hypothalamic-pituitary, thyroid, adrenal, gonadal, and GH/IGF-1 axes. Disorders such as acromegaly, growth hormone deficiency, hypothyroidism, hyperthyroidism, Cushing's syndrome, male and female hypogonadism, congenital adrenal hyperplasia, and polycystic ovary syndrome exhibit characteristic lipid abnormalities driven by hormonal dysregulation. These alterations contribute to increased cardiometabolic risk yet are frequently underrecognized and suboptimally managed. Early identification and tailored intervention may significantly improve outcomes.
CONCLUSION: Endocrine-related dyslipidemias represent a clinically relevant but often overlooked contributor to cardiovascular risk. By summarizing current evidence and expert perspectives, this Position Statement aims to support clinicians in improving diagnosis, risk stratification, and management of lipid disorders associated with endocrine diseases, fostering a multidisciplinary approach to cardiometabolic prevention.